A Phase 4 interventional study of biphasic insulin aspart 30 and biphasic insulin aspart 30 in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 69 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-02-24.
Sponsored by Novo Nordisk A/S · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 23rd largest by enrollment of the 197 interventional ones that give a count, is one of 16 that started in 2012, is one of 68 in phase 4, and was the 113th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Beijing Chao Yang Hospital · Sites in China
Ages 18–65
Bahria University · Sites in Pakistan
Ages 30–55
Yonsei University · Sites in Korea, Republic of
Ages 19–75
By country, each count listing its studies:
sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
198 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 11 · Phase 3 74 · Phase 4 68
First in 2003; this study’s year is marked. 16 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 582 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 102 across the 197 interventional studies. Of the 172 that completed or were terminated, 117 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
103 of 198 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S: 25 open now, 29 under way, 11 of them phase 3. Of 603 finished, 174 (29%) have results posted.
Among the 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 77th largest by enrollment of the 428 interventional ones that give a count, is one of 24 that started in 2012, is one of 75 in phase 4, and was the 275th registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
None of the studies under way reaches primary completion within a year.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 643 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This trial is conducted in Asia, Europe, Oceania and South America. The aim of this clinical trial is to generate data demonstrating how to intensify diabetes treatment using BIAsp 30 (biphasic insulin aspart 30) by adding or substituting BIAsp 30 to sitagliptin in various regimens for type 2 patients inadequately controlled on sitagliptin and metformin (with or without other oral anti-diabetic drugs (OADs)).
The trial is conducted as a phase 4 trial in the majority of the participating countries. However, in some countries the trial is conducted as phase 3b.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
This study's enrollment of 582 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: biphasic insulin aspart 30 · Drug: sitagliptin · Drug: metformin
Drug: biphasic insulin aspart 30 · Drug: metformin
Drug: biphasic insulin aspart 30 · Drug: sitagliptin · Drug: metformin
BIAsp 30 will be injected subcutaneously (under the skin) twice daily. Individually adjusted dose.
BIAsp 30 will be injected subcutaneously (under the skin) once daily. Individually adjusted dose.
Subjects will continue on their pre-trial sitagliptin treatment.
Subjects will continue on their pre-trial metformin treatment.
Change From Baseline in HbA1c (Glycosylated Haemoglobin)
Estimated mean change from baseline in HbA1c after 24 weeks of treatment.
Time frame: Week 0 to Week 24
Responder for HbA1c, Proportion of Subjects Achieving Pre-defined HbA1c Targets (HbA1c < 7.0%)
Proportion of subjects achieving HbA1c below 7.0% after 24 weeks of treatment
Time frame: After 24 weeks of treatment
Responder for HbA1c, Proportion of Subjects Achieving Pre-defined HbA1c Targets (HbA1c ≤ 6.5%)
Proportion of subjects achieving HbA1c equal to or below 6.5% after 24 weeks of treatment.
Time frame: After 24 weeks of treatment
Change From Baseline in Fasting Plasma Glucose (FPG)
Estimated mean change from baseline in fasting plasma glucose (FPG)
Time frame: Week 0 to Week 24
Prandial Plasma Glucose (PPG) Increments at Breakfast
Estimated mean post prandial increments at breakfast after 24 weeks of treatment.
Time frame: After 24 weeks of treatment
Prandial Plasma Glucose (PPG) Increments at Lunch.
Estimated mean post prandial increments at lunch after 24 weeks of treatment.
Time frame: After 24 weeks of treatment
Prandial Plasma Glucose (PPG) Increments at Dinner.
Estimated mean post prandial increments at dinner after 24 weeks of treatment.
Time frame: After 24 weeks of treatment
Prandial Plasma Glucose (PPG) Overall Mean Increment.
Estimated overall mean post prandial increment after 24 weeks of treatment.
Time frame: After 24 weeks of treatment
Adverse Events (AEs)
Rate of AEs per 100 years of patient exposure. An adverse event was defined as treatment emergent if the event had onset date on or after the first day of exposure to randomised treatment and no later than the last day of randomised treatment.
Time frame: Week 0 to Week 24
Number of Treatment Emergent Hypoglycaemic Episodes (Nocturnal and Day-time) Classified Both According to the American Diabetes Association (ADA) Definition and to an Additional Definition for Minor Episodes.
Number of treatment emergent hypoglycaemic episodes. Treatment emergent hypoglycaemic episode: if the onset of the episode was on or after the first day of exposure to randomised treatment and no later than the last day of randomised treatment. Nocturnal: Time of onset between 00:01 and 05:59 a.m. (both included). Additional minor hypoglycaemic episode: symptomatic or asymptomatic hypoglycaemia with blood glucose (BG) values \< 2.8 mmol/L (50 mg/dL) or plasma glucose (PG) \< 3.1 mmol/L (56 mg/dL), and which was handled by the subject him/herself.
Time frame: Week 0 to Week 24
Change From Baseline in Patient Reported Outcome by Use of the Treatment Related Impact Measure - Diabetes.
Estimated mean change from baseline in Treatment Related Impact Measure - Diabetes (TRIM-D) 'total score' to end of trial. The score measured treatment satisfaction. The scores were transformed to a 0-100 scale with higher scores indicating greater satisfaction.
Time frame: Week 0 to Week 24
The trial was conducted at 60 sites in 10 countries as follows: Argentina (6); Australia (2); Brazil (4); Greece (5); India (17); Malaysia (3); Portugal (6); Republic of Korea (7); Thailand (5); Turkey (5)
| Milestone | BID + Met | BID + Sita + Met | OD + Sita + Met |
|---|---|---|---|
| Started | 194 | 195 | 193 |
| Exposed | 192 | 193 | 190 |
| Completed | 173 | 182 | 181 |
| Not completed | 21 | 13 | 12 |
| Withdrew: Adverse event | 3 | 3 | 0 |
| Withdrew: Lack of efficacy | 1 | 1 | 1 |
| Withdrew: Protocol violation | 0 | 3 | 1 |
| Withdrew: Withdrawal criteria | 7 | 2 | 7 |
| Withdrew: Unsclassified | 10 | 4 | 3 |
Estimated mean change from baseline in HbA1c after 24 weeks of treatment.
| percentage of glycosylated haemoglobin | BID + Met | BID + Sita + Met | OD + Sita + Met |
|---|---|---|---|
| Change From Baseline in HbA1c (Glycosylated Haemoglobin) | -1.27 ± 0.07 | -1.51 ± 0.07 | -1.15 ± 0.07 |
Proportion of subjects achieving HbA1c below 7.0% after 24 weeks of treatment
| percentage (%) of subjects | BID + Met | BID + Sita + Met | OD + Sita + Met |
|---|---|---|---|
| Responder for HbA1c, Proportion of Subjects Achieving Pre-defined HbA1c Targets (HbA1c < 7.0%) | 49.7 | 59.8 | 46.5 |
Proportion of subjects achieving HbA1c equal to or below 6.5% after 24 weeks of treatment.
| percentage (%) of subjects | BID + Met | BID + Sita + Met | OD + Sita + Met |
|---|---|---|---|
| Responder for HbA1c, Proportion of Subjects Achieving Pre-defined HbA1c Targets (HbA1c ≤ 6.5%) | 30.6 | 40.7 | 25.1 |
Estimated mean change from baseline in fasting plasma glucose (FPG)
| mmol/L | BID + Met | BID + Sita + Met | OD + Sita + Met |
|---|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (FPG) | -1.90 ± 0.14 | -2.03 ± 0.14 | -1.96 ± 0.14 |
Estimated mean post prandial increments at breakfast after 24 weeks of treatment.
| mmol/L | BID + Met | BID + Sita + Met | OD + Sita + Met |
|---|---|---|---|
| Prandial Plasma Glucose (PPG) Increments at Breakfast | 2.01 ± 0.19 | 1.73 ± 0.19 | 2.89 ± 0.19 |
Estimated mean post prandial increments at lunch after 24 weeks of treatment.
| mmol/L | BID + Met | BID + Sita + Met | OD + Sita + Met |
|---|---|---|---|
| Prandial Plasma Glucose (PPG) Increments at Lunch. | 3.05 ± 0.22 | 2.19 ± 0.21 | 2.52 ± 0.21 |
Estimated mean post prandial increments at dinner after 24 weeks of treatment.
| mmol/L | BID + Met | BID + Sita + Met | OD + Sita + Met |
|---|---|---|---|
| Prandial Plasma Glucose (PPG) Increments at Dinner. | 0.89 ± 0.21 | 1.01 ± 0.20 | 0.17 ± 0.21 |
Estimated overall mean post prandial increment after 24 weeks of treatment.
| mmol/L | BID + Met | BID + Sita + Met | OD + Sita + Met |
|---|---|---|---|
| Prandial Plasma Glucose (PPG) Overall Mean Increment. | 1.97 ± 0.12 | 1.66 ± 0.12 | 1.88 ± 0.12 |
Rate of AEs per 100 years of patient exposure. An adverse event was defined as treatment emergent if the event had onset date on or after the first day of exposure to randomised treatment and no later than the last day of randomised treatment.
| Events/100 years of patient exposure | BID + Met | BID + Sita + Met | OD + Sita + Met |
|---|---|---|---|
| All treatment emergent adverse events | 262.2 | 209.9 | 281.2 |
| Serious adverse events | 8.4 | 5.8 | 10.5 |
| Severe adverse events | 6.0 | 10.5 | 7.0 |
| Moderate adverse events | 71.0 | 74.6 | 79.7 |
| Mild adverse events | 185.2 | 124.8 | 194.5 |
| Fatal adverse events | 0 | 0 | 0 |
Number of treatment emergent hypoglycaemic episodes. Treatment emergent hypoglycaemic episode: if the onset of the episode was on or after the first day of exposure to randomised treatment and no later than the last day of randomised treatment. Nocturnal: Time of onset between 00:01 and 05:59 a.m. (both included). Additional minor hypoglycaemic episode: symptomatic or asymptomatic hypoglycaemia with blood glucose (BG) values \< 2.8 mmol/L (50 mg/dL) or plasma glucose (PG) \< 3.1 mmol/L (56 mg/dL), and which was handled by the subject him/herself.
| episodes | BID + Met | BID + Sita + Met | OD + Sita + Met |
|---|---|---|---|
| Diurnal (ADA) | 515 | 440 | 249 |
| Nocturnal (ADA) | 68 | 54 | 63 |
| Diurnal (additional minor) | 163 | 112 | 71 |
| Nocturnal (additional minor) | 21 | 14 | 23 |
Estimated mean change from baseline in Treatment Related Impact Measure - Diabetes (TRIM-D) 'total score' to end of trial. The score measured treatment satisfaction. The scores were transformed to a 0-100 scale with higher scores indicating greater satisfaction.
| scores | BID + Met | BID + Sita + Met | OD + Sita + Met |
|---|---|---|---|
| Change From Baseline in Patient Reported Outcome by Use of the Treatment Related Impact Measure - Diabetes. | 6.22 ± 0.82 | 5.93 ± 0.81 | 6.20 ± 0.81 |
Collected over Adverse events were captured the onset date on or after the first day of exposure to randomised treatment and no later than the last day of randomised treatment.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BID + Met | — | 7/192 (3.6%) | 30/192 (15.6%) |
| BID + Sita + Met | — | 5/193 (2.6%) | 25/193 (13%) |
| OD + Sita + Met | — | 4/190 (2.1%) | 32/190 (16.8%) |
| Event | BID + Met | BID + Sita + Met | OD + Sita + Met |
|---|---|---|---|
| PyrexiaGeneral disorders | 0/192 | 0/193 | 1/190 |
| GastroenteritisInfections and infestations | 0/192 | 0/193 | 1/190 |
| HypoglycaemiaMetabolism and nutrition disorders | 1/192 | 1/193 | 1/190 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/192 | 0/193 | 1/190 |
| Haemorrhagic strokeNervous system disorders | 0/192 | 0/193 | 1/190 |
| Hypoglycaemic unconsciousnessNervous system disorders | 0/192 | 0/193 | 1/190 |
| AnaemiaBlood and lymphatic system disorders | 1/192 | 0/193 | 0/190 |
| Supraventricular tachycardiaCardiac disorders | 1/192 | 0/193 | 0/190 |
| Drug hypersensitivityImmune system disorders | 1/192 | 0/193 | 0/190 |
| Liver abscessInfections and infestations | 1/192 | 0/193 | 0/190 |
| Event | BID + Met | BID + Sita + Met | OD + Sita + Met |
|---|---|---|---|
| InfluenzaInfections and infestations | 11/192 | 5/193 | 10/190 |
| NasopharyngitisInfections and infestations | 9/192 | 11/193 | 8/190 |
| HeadacheNervous system disorders | 7/192 | 11/193 | 8/190 |
| DiarrhoeaGastrointestinal disorders | 8/192 | 1/193 | 10/190 |
| Age, Continuous(years) | BID + Met | BID + Sita + Met | OD + Sita + Met | Total |
|---|---|---|---|---|
| Mean | 54.8 ± 9.5 | 56.3 ± 10.2 | 55.7 ± 10.4 | 55.6 ± 10.0 |
| Gender(Participants) | BID + Met | BID + Sita + Met | OD + Sita + Met | Total |
|---|---|---|---|---|
| Female | 83 | 101 | 97 | 281 |
| Male | 111 | 94 | 96 | 301 |
| Body Weight(kg) | BID + Met | BID + Sita + Met | OD + Sita + Met | Total |
|---|---|---|---|---|
| Mean | 79.4 ± 15.8 | 78.3 ± 16.1 | 77.5 ± 16.8 | 78.4 ± 16.2 |
| Body Mass Index (BMI)(kg/m^2) | BID + Met | BID + Sita + Met | OD + Sita + Met | Total |
|---|---|---|---|---|
| Mean | 29.3 ± 4.3 | 29.4 ± 4.5 | 29.4 ± 5.0 | 29.4 ± 4.6 |
| Glycosylated haemoglobin (HbA1c)(Percent (%) glycosylated haemoglobin) | BID + Met | BID + Sita + Met | OD + Sita + Met | Total |
|---|---|---|---|---|
| Mean | 8.4 ± 0.8 | 8.4 ± 0.8 | 8.4 ± 0.8 | 8.4 ± 0.8 |
| Fasting plasma glucose (FPG)(mmol/L) | BID + Met | BID + Sita + Met | OD + Sita + Met | Total |
|---|---|---|---|---|
| Mean | 8.9 ± 2.2 | 9.3 ± 2.8 | 8.7 ± 2.7 | 9.0 ± 2.6 |
The record gives a start of Jun 2012, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2014, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sitagliptin